Skip to main content

Pairings: Dec 15, 2010


Epigenomics announced this week that Oliver Schacht, its current chief financial officer, has decided to leave the company after working there for nearly 13 years.

"We are very pleased that we already have found and signed-up a new chief financial officer, who will join the management team by April 1, 2011," Epigenomics said in a statement. However, due to the new hire's current obligations, Epigenomics will disclose the CFO's name in the first weeks of January 2011.

Schacht and the new CFO will work together during the first quarter to "ensure a smooth transition," Epigenomics said.

J&J has put out a call for nominations for its 2011 Dr. Paul Janssen Award for Biomedical Research. The $100,000 award recognizes scientists in academic and industrial research in the field of biomedical engineering, "whose efforts have made transformational contributions towards the improvement of human health."

Nomination forms are available here and will be accepted until February 15, 2011. The winner will be announced in the second half of next year.

Nominees will be evaluated by an independent selection committee of researchers from around the world. Past winners of the award include Anthony Fauci, Erik De Clercq, Craig Mello, Axel Ullrich, Marc Feldmann, and Ravinder Maini.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.